China BioPharma Held Sales Meeting for the Upcoming Flu Season.

ISELIN, N.J. -- Techedge Inc. (OTCBB:TEDG) announced that China BioPharma's subsidiary Zhejiang Tianyuan Biotech Co., held a successful sales meeting in Hangzhou, China last week with over 60 sales executives from all over the country were in attendance. The meeting addressed the vaccine demand and the company's sales plan in China for this year's flu vaccine sales season which starts this quarter.

China BioPharma has a distribution network throughout China covering most of the local provinces and major cities. Dr. Jean-Denis Shu, CEO of China BioPharma, Limited stated, "We have seen a strong demand of flu vaccines this year and our shipment of the flu vaccines is planned to start in August."

About Techedge, Inc.

Techedge, Inc. is a fast growing developer, producer, and distributor of biopharmaceutical products in China. It has wholly owned subsidiary, China BioPharma Limited and owns the majority interest of Zhejiang Tianyuan Biotech Co., Ltd ("ZTB"). The Company's current products consist of human vaccines against influenza, epidemic hemorrhagic fever (HFV), and Japanese Encephalitis (JEV) with high reputation and market shares among Chinese made vaccines. Through its investment and ownership of leading Chinese biopharmaceutical companies, the company plans to build the most efficient and most profitable biopharmaceutical company in China by introducing the most advanced technology, best product, and experienced management team. With a fast growing market, newly completed production facility, and several other new vaccines in the pipeline, it is expected to have a steady business growth. For more information, please visit its website at www.techedgeinc.net

FORWARD-LOOKING STATEMENT DISCLAIMER

Some of the statements made in this press release discuss future events and developments, including our future business strategy and our ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.